Arbutus and Genevant file patent lawsuit against Moderna

28 February 2022

Arbutus Biopharma’s (Nasdaq: ABUS) shares were up 4.3% at $3.21 after, along with, Genevant Sciences, today filed a lawsuit in the US District Court for the District of Delaware against Moderna (Nasdaq: MRNA) and one of its affiliates.

The lawsuit seeks damages for infringement of US Patent Nos 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use.

Moderna, which last week said it expects sales of its COVID-19 vaccine Spikevax to exceed $19 billion in sales this year, is also embroiled in a patent dispute with the federal government after it disputed claims that three scientists from the National Institutes of Health were co-inventors of the vaccine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK